These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 18024400)

  • 21. Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.
    Nivison-Smith I; Bradstock KF; Szer J; Durrant S; Dodds A; Hermann R; Schwarer AP; Gibson J; To LB; Arthur C;
    Bone Marrow Transplant; 2001 Jul; 28(1):21-7. PubMed ID: 11498740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients.
    Kim BK; Hong KT; Choi JY; Kim H; Park HJ; Kang HJ
    Ann Hematol; 2024 Jun; 103(6):2051-2058. PubMed ID: 38594416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
    Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.
    Shaw BE; Apperley JF; Russell NH; Craddock C; Liakopoulou E; Potter MN; Wynn R; Gibson B; Pearce RM; Kirkland K; Lee J; Madrigal JA; Cook G; Byrne JL
    Br J Haematol; 2011 Apr; 153(2):244-52. PubMed ID: 21382020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences between graft product and donor side effects following bone marrow or stem cell donation.
    Favre G; Beksaç M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szer J; Bradstock K; Buzyn A; Matcham J; Gratwohl A; Schmitz N;
    Bone Marrow Transplant; 2003 Nov; 32(9):873-80. PubMed ID: 14561987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry.
    del Cañizo MC; Martínez C; Conde E; Vallejo C; Brunet S; Sanz G; Mateos MV;
    Bone Marrow Transplant; 2003 Nov; 32(10):987-92. PubMed ID: 14595386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
    Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents.
    Remberger M; Ringdén O
    Transplantation; 2007 Aug; 84(4):551-4. PubMed ID: 17713443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
    Kim DH; Sohn SK; Lee NY; Baek JH; Kim JG; Won DI; Suh JS; Lee KB; Shin IH
    Eur J Haematol; 2005 Oct; 75(4):299-308. PubMed ID: 16146536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
    Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
    Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin NC; Mohty M; Rocha V
    J Clin Oncol; 2009 Sep; 27(27):4570-7. PubMed ID: 19652066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
    Isola LM; Scigliano E; Skerrett D; Shank B; Ross V; Najfeld V; Fruchtman S
    Bone Marrow Transplant; 1997 Dec; 20(12):1033-7. PubMed ID: 9466275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
    Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
    Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
    Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
    Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
    Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.